Jump to content

Epaminurad

From Wikipedia, the free encyclopedia

Epaminurad
Clinical data
Other namesURC102/UR-1102
Identifiers
  • (3,5-dibromo-4-hydroxyphenyl)-(2,3-dihydropyrido[4,3-b][1,4]oxazin-4-yl)methanone
CAS Number
PubChem CID
UNII
ChEMBL
Chemical and physical data
FormulaC14H10Br2N2O3
Molar mass414.053 g·mol−1
3D model (JSmol)
  • C1COC2=C(N1C(=O)C3=CC(=C(C(=C3)Br)O)Br)C=NC=C2
  • InChI=InChI=1S/C14H10Br2N2O3/c15-9-5-8(6-10(16)13(9)19)14(20)18-3-4-21-12-1-2-17-7-11(12)18/h1-2,5-7,19H,3-4H2
  • Key:ZMVGQIIOXCGAFV-UHFFFAOYSA-N

Epaminurad is an investigational new drug being developed by JW Pharmaceutical for the treatment of gout and hyperuricemia. It is a urate-lowering agent that selectively inhibits the human uric acid transporter 1 (hURAT1), promoting urate excretion.[1][2] As of 2024, epaminurad is undergoing Phase 3 clinical trials to evaluate its efficacy and safety compared to febuxostat in gout patients across multiple Asian countries.[3][1]

References

[edit]
  1. ^ a b "JW Pharmaceutical's Epaminurad Shows Promise for Gout Treatment". Business Korea. 16 January 2024. Retrieved 2024-11-23.
  2. ^ Hou X, Wang Y, Yang Y, Xiao Z (November 2023). "Discovery of Novel Biphenyl Carboxylic Acid Derivatives as Potent URAT1 Inhibitors". Molecules. 28 (21). Basel, Switzerland: 7415. doi:10.3390/molecules28217415. PMC 10648204. PMID 37959834.
  3. ^ Khaja H (9 February 2024). "Emerging Drug Treatments for Gout". Rheumatology Advisor. Retrieved 2024-11-23.